a operational today and and results. to Stephanie, through will Alexis review. I good XXXX our Thank financial you, earnings call. business fourth everyone Wallace, for will joining afternoon quarter us our conference year-end walking provide then and begin our Controller, by
the that for Following Wallace, Alexis Bates will Dr. Bates, call myself Ernie your questions. and open
X.X% X.X%, X,XXX fourth Health increased our quarter. in XXXX proton higher revenue growth, by proton quarter, therapy by X,XXX the quarter fractions system business compared good increasing XX volumes. with X,XXX,XXX driven the in to the proton continued to or therapy to Total fourth quarter-over-quarter to Orlando post the therapy for In
will increase, For therapy the increased expanding continues cancer of important to of were year, of growth Growing proton uses therapy the proton treatment XX%. continued benefits support awareness XX% this clinical the which revenue therapy. fractions up and the and full
was X.X% revenue to XX in of Knife Gamma Peru, XXX the ramping by as up Gamma increase of number quarter. in well Lima, increased procedures year's compared treating continued by in quarter to last January The Merrillville, Knife X,XXX,XXX. fourth The addition to the quarter began in the XXX in fourth facility XXXX. fourth new of site standalone as our by driven the patients procedures Indiana, which in in our increased
two average posted discussions business but hold first XXXX quarter in Knife the Icon in an also previously We've Cobalt-XX reloads MR/LINAC upgrade in for decline as contracted the placements a Gamma and the We of and quarter. parties for to Overall, reimbursement we additional PBRT existing volume, continued during completed disclosed. increase interested fourth customers. with with an
as continues expect the conversations in we deal the realistically, pandemic. COVID-XX these to and slowdown system healthcare a with However, country
business do expect tumors. COVID-XX on the significant is don't predominantly which on cancerous We an impact We the on proton virus. from business, a our with performed therapy patients impact expect
Assuming timely on remain near-term expect to a continue we patients volumes diagnosed steady. be basis, to
COVID-XX. Knife March. Gamma see due maybe sight volumes and considered procedures of XX% to are treatment in delayed We at approximately However, to non-urgent softening in subject some do
at the more hard impact be more during an this to second expect although We quarter of specific it's time.
this selected XX% on certain across oncology methodology. and providers current an payment bundled XXXX, and the based in and the that Services projects quarter the third suppliers. morning or included approximately receive services radiation new noted Medicaid mandatory is that call test model for announced for on this conference As continue to fee-for-service be episodic press our radiation reimbursement structure therapy and model in to will providers approximately radiation XX% our oncology discussed intended as proposed Medicare and release will payment centers CMS randomly July, payment of in
proposed services. The significantly model payment would oncology CMS's radiation alter for methodology payment
for reimbursement XX.X% of Medicare and the the commonly not Gamma proposed Knife. X.X% the for the therapy is approximately XX% the in model, included centers For used most to to codes proton proposed XXXX increase delivery
payment details The continue to and of model timing the remain proposed uncertain.
we potential proposed of As cannot impact a estimate result, adoption the of rule. the
to However, or informed the results. adversely that the for of we and delay current rates information radiation new our reimbursement environment. any expect revenues radiosurgery affect keep therapy received methodology it reimbursement in probably changes although reductions you and in is in financial administration could prudent a We'll
With Alexis the that, a discussion. I'll over call to turn Alexis? now for detailed financial